The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...

If you looked solely at its stock price, you might get the idea that Eli Lilly (NYSE: LLY) is having a bit of an off quarter.

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Since its approval in mid-March of 2024, sales of Rezdiffra are increasing expediciously, reaching $62.2 million in Q3, the drug's first full quarter on the market. A mere year ago, Madrigal had no ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

Viking aims to compete against market giants Eli Lilly and Novo Nordisk in the billion-dollar weight loss drug market. The ...